EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TAVR-in-TAVR with a balloon-expandable valve for paravalvular leak

Takashi Nagasaka, Vivek Patel, Ofir Koren, Alon Shechter, Tarun Chakravarty, Wen Cheng, Hideki Ishii, Hasan Jilaihawi, Mamoo Nakamura, Raj R Makkar

Frontiers in Cardiovascular Medicine · 19.03.2024 · 11

DOI: 10.3389/fcvm.2024.1374078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 19.03.2024. Verfasst von Takashi Nagasaka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, United States. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Paravalvular leak (PVL) is a severe complication of transcatheter aortic valve replacement (TAVR) that can lead to poor outcomes. TAVR-in-TAVR is a promising treatment for PVL; however, reports on its safety or efficacy are limited. In this study, we aimed to investigate the clinical outcomes of TAVR-in-TAVR using balloon-expandable prostheses for PVLs after TAVR.

Methods

We retrospectively analyzed data from patients who underwent TAVR-in-TAVR using balloon-expandable Sapien prostheses for PVL after an initial TAVR at our institution. The procedural success, in-hospital complications, all-cause mortality, and echocardiographic data for up to 2 years post-surgery were evaluated.

Results

In total, 31 patients with a mean age of 81.1 ± 7.9 years and mean Society of Thoracic Surgeons score of 8.8 ± 5.4% were identified. The procedural success rate of TAVR-in-TAVR was 96.8% (30/31). No in-hospital deaths, cardiac tamponade, or conversion to sternotomy occurred. Re-intervention was performed in only one patient (3.2%) during hospitalization. The all-cause mortality rates at 30 days and 2 years were 0% and 16.1%, respectively. A significant reduction in the PVL rate was observed at 30 days compared with that at baseline ( p < 0.01).

Discussion

Our findings suggest that TAVR-in-TAVR using balloon-expandable prostheses is safe and effective for PVL after TAVR with low complication rates and acceptable long-term outcomes. Further studies with larger sample sizes are needed to confirm our findings.

Schlagwörter

Stichwörter der Autor:innen

New York heart association functional classTAVR-in-TAVRballoon-expandable valveparavalvular leaktranscatheter aortic valve replacement

Autor:innen und Institutionen

  • Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, United States.
  • Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan.
  • Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
  • Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Zitieren

APA

Nagasaka, T., Patel, V., Koren, O., Shechter, A., Chakravarty, T., Cheng, W., Ishii, H., Jilaihawi, H., Nakamura, M., & Makkar, R. R. (2024). TAVR-in-TAVR with a balloon-expandable valve for paravalvular leak. Frontiers in Cardiovascular Medicine, 11. https://doi.org/10.3389/fcvm.2024.1374078

Vancouver

Nagasaka T, Patel V, Koren O, Shechter A, Chakravarty T, Cheng W, et al. TAVR-in-TAVR with a balloon-expandable valve for paravalvular leak. Frontiers in Cardiovascular Medicine. 2024;11. doi:10.3389/fcvm.2024.1374078

BibTeX
@article{Nagasaka2024,
  author = {Nagasaka, Takashi and Patel, Vivek and Koren, Ofir and Shechter, Alon and Chakravarty, Tarun and Cheng, Wen and Ishii, Hideki and Jilaihawi, Hasan and Nakamura, Mamoo and Makkar, Raj R},
  title = {TAVR-in-TAVR with a balloon-expandable valve for paravalvular leak},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2024},
  volume = {11},
  doi = {10.3389/fcvm.2024.1374078}
}
Kostenlos starten →